Literature DB >> 30334473

How to make P-glycoprotein (ABCB1, MDR1) harbor mutations and measure its expression and activity in cell cultures?

Pablo Zubiaur1, Miriam Saiz-Rodríguez1, Dora Koller1, María Carmen Ovejero-Benito1, Aneta Wojnicz1, Francisco Abad-Santos1,2,3.   

Abstract

Several polymorphisms have been identified in ABCB1, the gene encoding for the P-glycoprotein. This transporter alters the pharmacokinetics or effectiveness of drugs by excreting them from cells where it is expressed (e.g., blood-brain barrier, intestine or tumors). No consensus has been reached regarding the functional consequences of these polymorphisms in the transporter's function. The aim of this review was to describe a methodology that allows the assessment of P-gp function when harboring polymorphisms. We describe how to obtain cell lines with high expression levels of the transporter with polymorphisms and several tactics to measure its expression and activity. This methodology may help elucidate the contribution of polymorphisms in ABCB1 to drug pharmacokinetics, effectiveness and safety or to cancer chemotherapy failure.

Entities:  

Keywords:  ABCB1; P-glycoprotein; cell culture; pharmacogenomics; polymorphism

Mesh:

Substances:

Year:  2018        PMID: 30334473     DOI: 10.2217/pgs-2018-0101

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  1 in total

Review 1.  Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19).

Authors:  Pablo Zubiaur; Dora Koller; Miriam Saiz-Rodríguez; Marcos Navares-Gómez; Francisco Abad-Santos
Journal:  Clin Transl Sci       Date:  2020-09-16       Impact factor: 4.689

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.